Lineage Cell Therapeutics (LCTX) Expected to Announce Earnings on Thursday

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) is expected to release its earnings data before the market opens on Thursday, March 6th. Analysts expect Lineage Cell Therapeutics to post earnings of ($0.04) per share and revenue of $1.62 million for the quarter.

Lineage Cell Therapeutics Price Performance

LCTX opened at $0.53 on Wednesday. The business has a 50-day moving average price of $0.60. Lineage Cell Therapeutics has a 12-month low of $0.48 and a 12-month high of $1.61. The stock has a market cap of $117.44 million, a PE ratio of -4.44 and a beta of 1.21.

Analyst Ratings Changes

Several brokerages recently weighed in on LCTX. D. Boral Capital dropped their target price on Lineage Cell Therapeutics from $3.00 to $2.00 and set a “buy” rating for the company in a report on Tuesday, February 11th. HC Wainwright restated a “buy” rating and set a $9.00 target price on shares of Lineage Cell Therapeutics in a report on Tuesday, February 11th. Finally, Maxim Group dropped their target price on Lineage Cell Therapeutics from $5.00 to $3.00 and set a “buy” rating for the company in a report on Friday, January 10th.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.